Dose-sparing romidepsin regimen promising in cutaneous T-cell lymphoma

Patients with cutaneous T-cell lymphoma who respond to the standard romidepsin dosing regimen could benefit from transitioning to a dose-sparing schedule, suggests a case series published in JAMA Oncology.
Source: MedWire News - Category: Consumer Health News Tags: Lymphoma Source Type: news